78 results
8-K
EX-99.1
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
closing conditions related to the public offering and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results
8-K
EX-99.2
APVO
Aptevo Therapeutics Inc
15 Apr 24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4:17pm
in Aptevo's business or prospects; uncertainties related to market conditions, and changes in regulatory, social, macroeconomic, and political conditions
8-K
EX-99.1
APVO
Aptevo Therapeutics Inc
7 Mar 24
Other Events
8:56am
in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward
8-K
EX-99.1
5n5emjrc
5 Mar 24
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
8:15am
8-K
EX-99.1
qmb9g3yyq hd
14 Nov 23
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.1
ueahzpkvfywbm
10 Aug 23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
8:16am
8-K
EX-99.1
w5zmjad
18 Jul 23
Aptevo Announces Positive Duration of Remission Data
8:16am
8-K
EX-99.1
blh6j
11 May 23
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
8:15am
8-K
EX-99.1
7zlw60l
30 Mar 23
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
7:50am
8-K
EX-99.1
wuminiff1eng waicg
30 Mar 23
Entry into a Material Definitive Agreement
7:40am
8-K
EX-99.1
uw3mdo7
12 Dec 22
Other Events
8:17am
8-K
EX-99.1
2ix4jm7q
10 Nov 22
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
8:15am
8-K
EX-99.1
xrhdb1cui1iz4ym
19 Sep 22
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND
9:14am
8-K
EX-99.1
8mk8 qfqjoa9fl52
11 Aug 22
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8:15am
8-K
EX-99.1
hnii79
9 Jun 22
Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission
8:15am
8-K
EX-99.1
eihz z1mva6
12 May 22
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and One patient received APVO436 in a monotherapy cohort of the trial and experienced significant reduction in bone marrow blasts
8:15am